← Back to Search

Immune Activation Imaging for COVID-19

Phase < 1

Recruiting

Led By Timothy Henrich, MD

Research Sponsored by CellSight Technologies, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Calculated creatinine clearance (CrCl) ≥60 mL/min as estimated by the Cockcroft-Gault equation

Age >18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is studying a new imaging method to track the spread of the coronavirus in the body.

Who is the study for?

This trial is for adults over 18 who've recently had COVID-19, with symptoms starting at least 14 days ago or a positive test if asymptomatic. They must have certain blood cell counts and organ function levels, not be pregnant or breastfeeding, and agree to use two forms of birth control if applicable.Check my eligibility

What is being tested?

The study tests an imaging agent called [18F]F-AraG using PET-CT scans to see how it distributes in the body after COVID-19 infection. Participants will receive up to two microdoses of the tracer; one mandatory scan followed by an optional second scan four months later.See study design

What are the potential side effects?

As this is an exploratory imaging study involving a tracer used in PET-CT scans, specific side effects are not detailed but may include reactions related to intravenous injection and exposure to radiation from the imaging process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidneys are functioning well, with a creatinine clearance rate of 60 mL/min or higher.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

[18F]F-AraG uptake in participants with convalescent COVID-19

Secondary outcome measures

[18F]F-AraG uptake in female versus male participants

[18F]F-AraG uptake in participants with convalescent COVID-19 over time

[18F]F-AraG uptake in participants with mild to severe COVID-19 symptoms

Trial Design

1Treatment groups

Experimental Treatment

Group I: [18F]F-AraGExperimental Treatment1 Intervention

Radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) Trade name: VisAcT

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor

17 Previous Clinical Trials

291 Total Patients Enrolled

University of California, San FranciscoOTHER

2,506 Previous Clinical Trials

15,238,535 Total Patients Enrolled

Timothy Henrich, MDPrincipal InvestigatorUniversity of California, San Francisco

3 Previous Clinical Trials

102 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit for participants in this experiment?

"Indeed, according to the documents accessible on clinicaltrials.gov, this experiment is currently enrolling participants. It was first released on April 15th 2021 and its most recent update took place June 28th 2022. The research aims at recruiting 20 volunteers from a single medical centre."

Answered by AI

Does this research project accept participants at the current time?

"Affirmative. According to the information archived on clinicaltrials.gov, this medical experiment is still recruiting participants. This trial was first announced on April 15th 2021 and underwent a recent update on June 28th 2022. Presently, there is need for 20 volunteers from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Imaging Immune Activation in COVID-19

2021. "Imaging Immune Activation in COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04815096.

All > Coronavirus